...
首页> 外文期刊>Clinical and experimental obstetrics and gynecology >Infertility treatment by in vitro fertilization in patients with minimal or mild endometriosis.
【24h】

Infertility treatment by in vitro fertilization in patients with minimal or mild endometriosis.

机译:轻微或轻度子宫内膜异位症患者的体外受精不孕治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To estimate the clinical effectiveness of in vitro fertilization treatment in patients with minimal or mild endometriosis (stages I and II) in comparison to the patients with tubal infertility in terms of fertilization, pregnancy and livebirth rates. METHODS: Retrospective analysis of the outcome of IVF-ET in 612 cycles of the patients with endometriosis (389 stimulated with HMG/HCG and 223 co-treated with GnRH-a) and in 7,339 cycles of the patients with tubal infertility (5,520 stimulated with HMG/HCG and 1,819 co-treated with GnRH-a). RESULLTS: Regardless of the type of ovarian stimulation, the fertilization rate per treated cycle was practically the same in both groups (endometriosis 81.4% vs tubal infertility 84.2%; p = 0.07). However, in the endometriosis group the pregnancy rate was higher (25.3% vs 18.9%; p = 0.000), and so was the livebirth rate (19.0% vs 14.2%; p = 0.003). Considering the type of ovarian stimulation, the fertilization rate in the endometriosis group was almost the same in the HMG/HCG (81.2%) and in the GnRH-a co-treated cycles (81.6%), and did not differ from that in the tubal infertility group (83.6% in the HMG/HCG vs 85.9% in the GnRH-a cycles). In the GnRH-a co-treated cycles the pregnancy rate and the livebirth rate were not significantly higher in the endometriosis group than in the tubal infertility group (27% and 20.2% vs 22.2% and 17.5%). In the HMG/HCG stimulated cycles the pregnancy rate was significantly higher in the endometriosis than in the tubal infertility group (24.3% vs 17.7%; p = 0.004), and so was the livebirth rate (18.4% vs 13.0%; p = 0.008). CONCLUSION: In patients with minimal or mild endometriosis the IVF-ET procedure is at least as effective as in patients with tubal infertility.
机译:目的:在受精,妊娠和分娩率方面,与输卵管性不育患者相比,评估具有最小或轻度子宫内膜异位症(I和II期)的患者的体外受精治疗的临床效果。方法:回顾性分析子宫内膜异位患者612周期(HMG / HCG刺激389例和GnRH-a联合治疗223例)和输卵管性不育患者7,339周期(5,520例经子宫内膜异位症刺激)的IVF-ET结局HMG / HCG和1,819与GnRH-a共同处理)。结果:不管卵巢刺激的类型如何,两组每个治疗周期的受精率实际上都是相同的(子宫内膜异位症为81.4%,输卵管不育症为84.2%; p = 0.07)。但是,子宫内膜异位组的妊娠率较高(25.3%对18.9%; p = 0.000),而活产率也较高(19.0%对14.2%; p = 0.003)。考虑到卵巢刺激的类型,子宫内膜异位症组的受精率在HMG / HCG组和GnRH-a联合治疗组中分别为81.2%和81.6%,与子宫内膜异位组的受精率几乎相同。输卵管不育组(HMG / HCG组为83.6%,GnRH-a周期为85.9%)。在GnRH-a联合治疗的周期中,子宫内膜异位组的妊娠率和分娩率没有明显高于输卵管不育组(27%和20.2%对22.2%和17.5%)。在HMG / HCG刺激的周期中,子宫内膜异位症的妊娠率显着高于输卵管不育症组(24.3%vs. 17.7%; p = 0.004),而分娩率也是如此(18.4%vs 13.0%; p = 0.008) )。结论:在子宫内膜异位症轻度或轻度的患者中,IVF-ET程序至少与输卵管性不育患者一样有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号